These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 22257796)
1. Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications. George EM; Palei AC; Granger JP Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):157-62. PubMed ID: 22257796 [TBL] [Abstract][Full Text] [Related]
2. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779 [TBL] [Abstract][Full Text] [Related]
3. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies. Holme AM; Roland MC; Henriksen T; Michelsen TM Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620 [TBL] [Abstract][Full Text] [Related]
4. From placenta to podocyte: vascular and podocyte pathophysiology in preeclampsia. Wagner SJ; Craici IM; Grande JP; Garovic VD Clin Nephrol; 2012 Sep; 78(3):241-9. PubMed ID: 22874114 [TBL] [Abstract][Full Text] [Related]
5. Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. Palmer KR; Kaitu'u-Lino TJ; Hastie R; Hannan NJ; Ye L; Binder N; Cannon P; Tuohey L; Johns TG; Shub A; Tong S Hypertension; 2015 Dec; 66(6):1251-9. PubMed ID: 26416849 [TBL] [Abstract][Full Text] [Related]
6. Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? Karumanchi SA; Epstein FH Kidney Int; 2007 May; 71(10):959-61. PubMed ID: 17495934 [TBL] [Abstract][Full Text] [Related]
7. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405 [TBL] [Abstract][Full Text] [Related]
8. Endothelin: key mediator of hypertension in preeclampsia. George EM; Granger JP Am J Hypertens; 2011 Sep; 24(9):964-9. PubMed ID: 21677700 [TBL] [Abstract][Full Text] [Related]
9. The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Tal R Biol Reprod; 2012 Jun; 87(6):134. PubMed ID: 23034156 [TBL] [Abstract][Full Text] [Related]
10. Vascular mechanisms and molecular targets in hypertensive pregnancy and preeclampsia. Qu H; Khalil RA Am J Physiol Heart Circ Physiol; 2020 Sep; 319(3):H661-H681. PubMed ID: 32762557 [TBL] [Abstract][Full Text] [Related]
11. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. Kaitu'u-Lino TJ; Brownfoot FC; Hastie R; Chand A; Cannon P; Deo M; Tuohey L; Whitehead C; Hannan NJ; Tong S Hypertension; 2017 Nov; 70(5):1014-1024. PubMed ID: 28947613 [TBL] [Abstract][Full Text] [Related]